Colchicine Toxicity and Management Strategies

Colchicine is a longstanding therapeutic agent for gout, familial Mediterranean fever and pericarditis. Its narrow therapeutic index means that effective and toxic doses are closely aligned, leading to a pronounced risk of overdose and adverse outcomes. Toxicity typically evolves through an early gastrointestinal phase marked by nausea, vomiting and diarrhoea, followed by a latent period and then a multiorgan phase with bone marrow suppression, cardiac arrhythmias, respiratory failure and acute kidney injury. Fatalities often result from cardiovascular collapse, sepsis or persistent organ dysfunction. Current management strategies centre on rapid recognition, supportive intensive care and targeted interventions to enhance toxin removal or neutralise free drug. Approaches range from gastrointestinal decontamination with activated charcoal to extracorporeal techniques such as plasmapheresis and renal replacement therapy. Emerging antidotal strategies, notably colchicine-specific Fab fragments, show promise in preclinical models for binding free colchicine and preventing cellular uptake, but require clinical validation. Public health measures and patient education to ensure correct dosing, safe storage and avoidance of high-risk drug combinations are crucial to reduce incidence of poisoning.

Research from Nature Portfolio

No recent Nature Portfolio content available.

Colchicine Toxicity and Management Strategies publication trend

The graph below shows the total number of articles in colchicine toxicity and management strategies across all publications each year (not limited to Nature Index journals).

Technical terms

Narrow therapeutic index: A small margin between therapeutic and toxic doses, necessitating precise dosing and monitoring to avoid adverse effects.

Myotoxicity: Muscle cell injury or death often manifesting as weakness, pain or elevated creatine kinase levels, which can be triggered by colchicine alone or in combination with other drugs.

Plasmapheresis: An extracorporeal technique that filters plasma to remove circulating toxins or antibodies, potentially reducing free colchicine levels.

Continuous renal replacement therapy (CRRT): A slow, continuous form of dialysis used in critically ill patients to support kidney function and extract water-soluble toxins over prolonged periods.

Fab fragments: Antigen-binding fragments of immunoglobulins that can be engineered to bind and neutralise specific toxins such as colchicine in the bloodstream.

References

1. Muscular toxicity of colchicine combined with statins: a real-world study based on the FDA adverse event reporting system database from 2004–2023. Frontiers in Pharmacology (2024).
2. Colchicine: the good, the bad, the ugly and how to minimize the risks. Rheumatology (2023).
3. Anti-colchicine Fab fragments prevent lethal colchicine toxicity in a porcine model: a pharmacokinetic and clinical study. Journal of Toxicology Clinical Toxicology (2018).
4. Severe colchicine poisoning treated successfully with kidney replacement therapy and plasmapheresis: a case report. Toxicology Communications (2022).